+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
ID05402072

Comparing Autologous Matrix-Induced Chondrogenesis and Microfracture Surgery for Hip Cartilage Damage A Pilot Randomized Trial

Led by McMaster University · Updated on 2026-10-07

40

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a pilot randomized controlled trial to compare two surgical techniques for treating focal articular cartilage defects in the hip. The study includes 40 patients aged 18 to 55 years undergoing primary hip arthroscopy, aiming to evaluate hip function, quality of life, pain, cartilage regeneration, health utility, and adverse events over a 2-year period. This study addresses the effects of autologous matrix-induced chondrogenesis AMIC versus the standard microfracture treatment. Participants will receive hip arthroscopy where unstable cartilage is removed and microfracture is performed by creating tiny perforations in the bone. Those in the AMIC group will additionally have a collagen matrix implant placed over the defect to support cartilage repair. Follow-up visits are scheduled at 6 weeks, 6 months, 12 months, 18 months, and 24 months post-surgery to monitor progress. During the study, participants will undergo assessments including hip function and quality of life measured by the International Hip Outcome Tool iHOT-33, hip pain using a visual analogue scale, cartilage repair evaluated by MRI scoring, health utility, and monitoring for adverse events. The total participation time is 2 years, with multiple evaluations to track recovery and treatment impact.

CONDITIONS

Brief Title

AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip

Research Team

N

Nicole Simunovic, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here